tirzepatide weight loss clinical trial results once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 Tirzepatide is FDA-approved for weight

These results underscore the possibility of using genetic markers and antioxidant medicines to enhance chemotherapy efficacy and mitigate adverse effects

They're very effective in weight loss." Patients do report side effects like bloating and constipation

Acknowledgements This work was supported by the Research Fund of Ghent University, Belgium, grant BOF08/GOA/004 and BOF14/GOA/010 and Fonds Wetenschappelijk Onderzoek Vlaanderen (grant FWO14/PDO/067)

Product labelling and official guidance highlight important safety issues, including gastrointestinal adverse effects and warnings around use in appropriate patient groups

Whether youre an HR professional, a business owner, or someone whos just received a distressing test result, well empower you with the knowledge to challenge the findings effectively